BRIVIACT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BRIVIACT (BRIVIACT).
Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.
| Metabolism | Primarily hydrolyzed by amidase to a carboxylic acid metabolite (approximately 95% of dose). Minor oxidation by CYP2C19 and CYP2C9. |
| Excretion | Approximately 95% of the dose is excreted in urine as metabolites or unchanged drug (<1% unchanged). About 0.8% is excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 9 hours (range 7–11 hours). This supports a twice-daily dosing regimen (e.g., 50 mg twice daily) with steady state achieved within approximately 2 days. |
| Protein binding | ≤20% bound to plasma proteins, predominantly albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.5 L/kg (range 0.3–0.6 L/kg), indicating distribution into total body water and extensive tissue binding. |
| Bioavailability | Oral: Essentially complete absorption with absolute oral bioavailability >90% (for tablets and solution). IV: 100% bioavailability. |
| Onset of Action | Oral (tablets/solution): Peak plasma concentrations occur at approximately 1 hour (fasting) to 2–3 hours (with food). Clinical effect (seizure reduction) typically begins within the first week of therapeutic dosing. Intravenous (IV): Rapidly distributed; clinical effect expected within minutes of infusion completion (~15 min infusion). |
| Duration of Action | Duration of antiepileptic effect is approximately 12 hours based on dosing interval (twice daily). Maintenance of therapeutic plasma levels over 24 hours requires regular 12-hourly dosing. |
| Action Class | Synaptic vescicle 2 A protein ligand (AED) |
| Brand Substitutes | Brivapride 50mg Tablet, Brinda 50 Tablet, Brivalex 50mg Tablet, Briv + 50mg Tablet, Bricet 50mg Tablet, Brivanext 100mg Tablet, Brivalex 100mg Tablet, Bripca 100mg Tablet, Brivatop 100 Tablet, Britam 100mg Tablet, Brivanext 75mg Tablet, Bevicet 75mg Tablet, Brivepsy 75mg Tablet, Brivatab 75 Tablet, Vivocet 75 Tablet |
50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.
| Dosage form | SOLUTION |
| Renal impairment | For GFR ≥50 mL/min: no adjustment. For GFR 30-49 mL/min: 50 mg twice daily. For GFR <30 mL/min: 25 mg twice daily. Hemodialysis: 25 mg once daily with supplemental dose (up to 50 mg) after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 25 mg twice daily (reduce by 50%). Child-Pugh C: not recommended. |
| Pediatric use | For ≥1 month to <16 years: initial 1-2 mg/kg/day divided twice daily; titrate to 2-4 mg/kg/day; maximum 200 mg/day. Weight-based dosing: 5-10 kg: 5-10 mg twice daily; 10-20 kg: 10-20 mg twice daily; 20-40 kg: 20-40 mg twice daily; >40 kg: 50-100 mg twice daily. |
| Geriatric use | No specific dose adjustment; initiate at 50 mg twice daily with caution; consider renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BRIVIACT (BRIVIACT).
| Breastfeeding | Brivaracetam is excreted into human breast milk. The milk-to-plasma (M/P) ratio has been reported as approximately 0.6-1.0 based on limited data. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Caution is advised due to potential for CNS adverse effects in breastfed infants. Monitor infant for sedation, poor feeding, and developmental milestones. The American Academy of Pediatrics considers brivaracetam compatible with breastfeeding, but individual risk-benefit assessment is recommended. |
| Teratogenic Risk | Based on animal studies and limited human data, brivaracetam (Briviact) is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. In the second and third trimesters, exposure may be associated with adverse neurodevelopmental outcomes. The risk is dose-dependent and may be potentiated by concomitant use of other antiepileptic drugs. Preclinical studies have shown increased fetal loss, growth retardation, and skeletal abnormalities at clinically relevant doses. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to brivaracetam or any component of the formulation"]
| Precautions | ["Suicidal behavior and ideation","Neurologic adverse reactions (somnolence, dizziness, ataxia, gait disturbance)","Behavioral and psychiatric reactions (including aggression, agitation, anger, anxiety, depression, irritability, psychosis)","Hypersensitivity reactions (including angioedema)","Withdrawal of antiepileptic drugs (increase seizure frequency)","Potential for QT prolongation (though not observed in studies, caution with other QT-prolonging drugs)"] |
| Food/Dietary | No significant food interactions. Grapefruit juice does not affect brivaracetam exposure. Alcohol may potentiate CNS depression and should be avoided or limited. High-fat meals do not alter absorption significantly. |
Loading safety data…
| Fetal Monitoring | Monitor maternal brivaracetam serum concentrations at least once per trimester and after delivery, with target trough levels within therapeutic range (typically 0.5-2.0 mcg/mL). Perform detailed fetal ultrasound at 18-22 weeks to assess for major malformations, including neural tube defects. Consider fetal echocardiography in high-risk cases. After birth, monitor the neonate for sedation, withdrawal symptoms (e.g., irritability, feeding difficulties), and metabolic disturbances. Periodic liver function tests and complete blood counts are recommended for the mother. |
| Fertility Effects | Brivaracetam has not been associated with significant effects on human fertility in clinical studies. Animal studies showed no adverse effects on male or female fertility at doses up to 4 times the maximum recommended human dose. However, as with other antiepileptic drugs, hormonal contraceptive efficacy may be reduced due to potential enzyme induction, though brivaracetam has less potential for drug interactions than older agents. Patients should use additional contraceptive methods if pregnancy is not planned. |
| Clinical Pearls | Brivaracetam is a high-affinity SV2A ligand similar to levetiracetam but with higher lipophilicity and brain penetration. Titration is not required; start at therapeutic dose. Monitor for psychiatric symptoms (irritability, aggression, depression) and somnolence. No need for therapeutic drug monitoring as efficacy correlates poorly with serum levels. Renal dose adjustment required for CrCl <30 mL/min. Bioavailability is nearly 100% with oral administration; IV formulation available for short-term substitution. Avoid abrupt discontinuation (seizure exacerbation possible). |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without talking to your doctor, as seizures may worsen. · May cause dizziness, drowsiness, or problems with coordination. Do not drive or operate heavy machinery until you know how the drug affects you. · Notify your doctor if you experience mood changes, depression, aggression, or thoughts of self-harm. · Briviact can be taken with or without food. If you miss a dose, take it as soon as you remember, unless it is close to your next dose; then skip the missed dose. · Inform your healthcare provider of all medications you take, especially alcohol, other seizure drugs, or blood thinners. · Women of childbearing potential: discuss birth control options, as brivaracetam may reduce effectiveness of hormonal contraceptives (though less than some other anticonvulsants). · Store at room temperature, away from moisture and heat. |